TapewireFind a company

person · Reporting owner

Ware J. Anthony

Disclosed activity across 2 companies

Tapewire entity
10095
SEC CIK
0001715429

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ANAPTYSBIO, INCANAB · Entity 4640DirectorJanuary 06, 2026January 08, 2026
First Tracks Biotherapeutics, Inc.TRAX · Entity 4696DirectorSeptember 02, 2026September 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ANAPTYSBIO, INC

Report date January 06, 2026 · Filed January 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.91 · Expires 2036-01-05Direct5,500 Reported balance After 2026-01-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-06 · Grant · Acquired 5,500 · Balance 5,500

F1: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Restricted Stock UnitSEC Table II · derivative / convertible securityDirect4,000 Reported balance After 2026-01-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-01-06 · Grant · Acquired 4,000 · Balance 4,000

F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

First Tracks Biotherapeutics, Inc.

Report date September 02, 2026 · Filed September 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect15,660 Ending reported balance After 2026-09-02 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-09-02 · Exercise / conversion · Acquired 39,265 · Balance 54,925

Row 2 · 2026-09-02 · Sale · Disposed 39,265 · Balance 15,660

F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.62 to $45.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.74 · Expires 2027-08-21Direct0 Reported balance After 2026-09-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-09-02 · Exercise / conversion · Disposed 28,571 · Balance 0

F2: The stock option is fully vested.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.74 · Expires 2027-08-21Direct0 Reported balance After 2026-09-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-09-02 · Exercise / conversion · Disposed 10,694 · Balance 0

F2: The stock option is fully vested.

F3: In addition to the shares the Reporting Person owns reported in Table I, the Reporting Person also holds additional options to purchase up to an aggregate of 99,320 shares of common stock and 6,500 restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.62 to $45.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The stock option is fully vested.

F3: In addition to the shares the Reporting Person owns reported in Table I, the Reporting Person also holds additional options to purchase up to an aggregate of 99,320 shares of common stock and 6,500 restricted stock units.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 02, 2026 Filed Sep 4, 2026 20:25 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 Exercise / conversionStock Option (right to buy) · Derivative 10,694 $0.00 Strike: $5.74 $0.00
Disclosure

SEC source: 0001715429-26-000007 · form4-09042026_080925.xml · derivative · entry 4

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,694 shares

Expires 2027-08-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option is fully vested.

F3 · balance_after: In addition to the shares the Reporting Person owns reported in Table I, the Reporting Person also holds additional options to purchase up to an aggregate of 99,320 shares of common stock and 6,500 restricted stock units.

Read SEC document
September 02, 2026 Filed Sep 4, 2026 20:25 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 Exercise / conversionStock Option (right to buy) · Derivative 28,571 $0.00 Strike: $5.74 $0.00
Disclosure

SEC source: 0001715429-26-000007 · form4-09042026_080925.xml · derivative · entry 3

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,571 shares

Expires 2027-08-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option is fully vested.

Read SEC document
September 02, 2026 Filed Sep 4, 2026 20:25 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 SaleCommon Stock 39,265 $44.78 $1,758,145.35
Disclosure

SEC source: 0001715429-26-000007 · form4-09042026_080925.xml · nonDerivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,660

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.62 to $45.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 02, 2026 Filed Sep 4, 2026 20:25 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 Exercise / conversionCommon Stock 39,265 $5.74 $225,381.10
Disclosure

SEC source: 0001715429-26-000007 · form4-09042026_080925.xml · nonDerivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,925

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 15, 2026 Filed Jun 17, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 Exercise / conversionRestricted Stock Unit · Derivative 6,030 $0.00 $0.00
Disclosure

SEC source: 0001715429-26-000006 · form4-06172026_040619.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,030 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
June 15, 2026 Filed Jun 17, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 Exercise / conversionCommon Stock 6,030 $0.00 $0.00
Disclosure

SEC source: 0001715429-26-000006 · form4-06172026_040619.xml · nonDerivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Read SEC document
May 12, 2026 Filed May 14, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 42,000 $0.00 Strike: $17.81 $0.00
Disclosure

SEC source: 0001715429-26-000004 · form4-05142026_040518.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2036-05-11

F3 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F4 · balance_after: In addition to the options to purchase a total of 42,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 131,585 shares of common stock, which options vest according to their terms.

Read SEC document
May 12, 2026 Filed May 14, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantRestricted Stock Unit · Derivative 15,000 $0.00 $0.00
Disclosure

SEC source: 0001715429-26-000004 · form4-05142026_040518.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
May 12, 2026 Filed Jun 12, 2026 20:01 UTC Amendment First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 7,000 $0.00 Strike: $17.81 $0.00
Disclosure

SEC source: 0001715429-26-000005 · form4a-06122026_080644.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2036-05-11

F3 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
May 12, 2026 Filed Jun 12, 2026 20:01 UTC Amendment First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantRestricted Stock Unit · Derivative 2,500 $0.00 $0.00
Disclosure

SEC source: 0001715429-26-000005 · form4a-06122026_080644.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantRestricted Stock Unit · Derivative 4,000 $0.00 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 14

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F6 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F8 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F8 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantRestricted Stock Unit · Derivative 6,030 $0.00 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 13

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,030

Underlying: Common Stock · 6,030 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F6 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F7 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F7 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 5,500 $0.00 Strike: $11.75 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 12

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Stock · 5,500 shares

Expires 2036-01-06

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F4 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 16,510 $0.00 Strike: $3.97 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 11

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,510

Underlying: Common Stock · 16,510 shares

Expires 2035-01-06

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 16,510 $0.00 Strike: $5.67 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 10

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,510

Underlying: Common Stock · 16,510 shares

Expires 2034-01-02

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 10,600 $0.00 Strike: $6.22 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 9

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,600

Underlying: Common Stock · 10,600 shares

Expires 2033-01-05

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 9,200 $0.00 Strike: $8.14 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 8

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,200

Underlying: Common Stock · 9,200 shares

Expires 2032-02-09

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $7.95 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 7

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2031-02-09

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $4.43 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 6

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2030-02-11

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 6,000 $0.00 Strike: $18.43 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 5

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2029-02-07

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 6,000 $0.00 Strike: $28.03 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 4

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2028-02-01

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 10,694 $0.00 Strike: $5.74 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 3

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,694

Underlying: Common Stock · 10,694 shares

Expires 2027-08-21

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 20:05 UTC First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 GrantStock Option (right to buy) · Derivative 28,571 $0.00 Strike: $5.74 $0.00
Disclosure

SEC source: 0001715429-26-000003 · form4-04222026_040417.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,571

Underlying: Common Stock · 28,571 shares

Expires 2027-08-21

F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
January 06, 2026 Filed Jan 8, 2026 21:03 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantRestricted Stock Unit · Derivative 4,000 $0.00 $0.00
Disclosure

SEC source: 0001715429-26-000001 · form4-01082026_090158.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 06, 2026 Filed Jan 8, 2026 21:03 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 5,500 $0.00 Strike: $43.91 $0.00
Disclosure

SEC source: 0001715429-26-000001 · form4-01082026_090158.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Stock · 5,500 shares

Expires 2036-01-05

F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
December 23, 2025 Filed Dec 23, 2025 21:30 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 3,900 $49.58 $193,342.50
Disclosure

SEC source: 0001715429-25-000003 · form4-12232025_091216.xml · nonDerivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,630

F1 · balance_after: In addition to the shares the Reporting Person owns reported in Table I, the Reporting Person also holds additional options to purchase up to an aggregate of 126,085 shares of common stock and 6,030 restricted stock units.

Read SEC document
June 15, 2025 Filed Jun 17, 2025 22:29 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionRestricted Stock Unit · Derivative 6,030 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-017586 · form4-06172025_100608.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,030 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
June 15, 2025 Filed Jun 17, 2025 22:29 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionCommon Stock 6,030 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-017586 · form4-06172025_100608.xml · nonDerivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,530

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Read SEC document
January 07, 2025 Filed Jan 7, 2025 22:28 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantRestricted Stock Unit · Derivative 6,030 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-001035 · form4-01072025_100157.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,030

Underlying: Common Stock · 6,030 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 07, 2025 Filed Jan 7, 2025 22:28 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 16,510 $0.00 Strike: $14.83 $0.00
Disclosure

SEC source: 0001415889-25-001035 · form4-01072025_100157.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,510

Underlying: Common Stock · 16,510 shares

Expires 2035-01-06

F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 7, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
June 15, 2024 Filed Jun 19, 2024 00:16 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionRestricted Stock Unit · Derivative 3,900 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-017509 · form4-06192024_120621.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,900 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
June 15, 2024 Filed Jun 19, 2024 00:16 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionCommon Stock 3,900 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-017509 · form4-06192024_120621.xml · nonDerivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Read SEC document
January 03, 2024 Filed Jan 5, 2024 21:51 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantRestricted Stock Unit · Derivative 6,030 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-001043 · doc4.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,030

Underlying: Common Stock · 6,030 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 03, 2024 Filed Jan 5, 2024 21:51 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 16,510 $0.00 Strike: $21.19 $0.00
Disclosure

SEC source: 0001209191-24-001043 · doc4.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,510

Underlying: Common Stock · 16,510 shares

Expires 2034-01-02

F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 3, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 06, 2023 Filed Jan 11, 2023 00:14 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantRestricted Stock Unit · Derivative 3,900 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-002888 · doc4.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,900

Underlying: Common Stock · 3,900 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 06, 2023 Filed Jan 11, 2023 00:14 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 10,600 $0.00 Strike: $23.23 $0.00
Disclosure

SEC source: 0001209191-23-002888 · doc4.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,600

Underlying: Common Stock · 10,600 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
February 10, 2022 Filed Feb 14, 2022 21:41 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 9,200 $0.00 Strike: $30.44 $0.00
Disclosure

SEC source: 0001209191-22-009315 · doc4.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,200

Underlying: Common Stock · 9,200 shares

Expires 2032-02-09

F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
February 10, 2021 Filed Feb 13, 2021 02:24 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $29.70 $0.00
Disclosure

SEC source: 0001209191-21-010512 · doc4.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2031-02-09

F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
February 12, 2020 Filed Feb 13, 2020 22:10 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantDirector Stock Option (Right to Buy) · Derivative 11,000 $0.00 Strike: $16.56 $0.00
Disclosure

SEC source: 0001209191-20-009329 · doc4.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2030-02-11

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 12, 2020, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Read SEC document
December 10, 2019 Filed Feb 6, 2020 22:48 UTC ANAPTYSBIO, INC ANAB · Entity 4640 PurchaseCommon Stock 3,600 $14.05 $50,580.00
Disclosure

SEC source: 0001209191-20-007251 · doc4.xml · nonDerivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,600

Read SEC document
February 08, 2019 Filed Feb 11, 2019 22:41 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantDirector Stock Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $68.89 $0.00
Disclosure

SEC source: 0001209191-19-009046 · doc4.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2029-02-07

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 8, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Read SEC document
February 02, 2018 Filed Feb 6, 2018 21:22 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantDirector Stock Option (right to buy) · Derivative 6,000 $0.00 Strike: $104.81 $0.00
Disclosure

SEC source: 0001209191-18-007840 · doc4.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2028-02-01

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Read SEC document
August 22, 2017 Filed Aug 24, 2017 22:41 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantDirector Stock Option (right to buy) · Derivative 10,694 $0.00 Strike: $21.45 $0.00
Disclosure

SEC source: 0001209191-17-050211 · doc4.xml · derivative · entry 2

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,694

Underlying: Common Stock · 10,694 shares

Expires 2027-08-21

F2 · derivative.exercise_date: The stock option vests and becomes fully exercisable on May 30, 2018.

Read SEC document
August 22, 2017 Filed Aug 24, 2017 22:41 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantDirector Stock Option (right to buy) · Derivative 28,571 $0.00 Strike: $21.45 $0.00
Disclosure

SEC source: 0001209191-17-050211 · doc4.xml · derivative · entry 1

Ware J. Anthony · CIK 0001715429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,571

Underlying: Common Stock · 28,571 shares

Expires 2027-08-21

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 36 equal monthly installments beginning on September 22, 2017, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.